Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Krystal Biotech (KRYS) welcomed the European Medicines Agency’s announcement that its Committee for Medicinal Products for Human Use has issued ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...

Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of ...

Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...

"The CHMP's recommendation for approval of VYJUVEK is an exciting step towards our goal of delivering the first ever corrective therapy to DEB patients across Europe,” said Suma Krishnan, President of ...

Krystal Biotech, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for VYJUVEK® (beremagene geperpavec-svdt ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...